S
Stephan A. Grupp
Researcher at Children's Hospital of Philadelphia
Publications - 396
Citations - 44427
Stephan A. Grupp is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Transplantation. The author has an hindex of 77, co-authored 366 publications receiving 34450 citations. Previous affiliations of Stephan A. Grupp include University of Pennsylvania & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
Targetting CD38 in T Cell Acute Lymphoblastic Leukemia
Karen L. Bride,Tiffaney Vincent,Soo-Yeon L. Im,David M. Barrett,Michelle L. Hermiston,Terzah M. Horton,Mignon L. Loh,Shannon L. Maude,Stephan A. Grupp,Brent L. Wood,David T. Teachey +10 more
Posted ContentDOI
Impaired tumor death receptor signaling drives resistance to CAR T cell therapy
Nathan Singh,Olga Shestova,Pranali Ravikumar,Katharina E. Hayer,Seok Jae Hong,Elena Orlando,Karen Thudium Mueller,Charly R. Good,Shelley L. Berger,Ophir Shalem,Ophir Shalem,Matthew D. Weitzman,Matthew D. Weitzman,Stephan A. Grupp,Carl H. June,Saar Gill,Marco Ruella +16 more
TL;DR: It is demonstrated that death receptors, cell surface signaling molecules that induce target cell apoptosis, are key mediators of leukemic resistance and CART19 failure and that tumor-intrinsic death receptor signaling directly contributes to CAR T cell failure.
Proceedings ArticleDOI
Abstract 1537: Anti-CD19 ARTEMIS™ T cells prevent excessive inflammatory cytokine release, including IL-6, in a co-culture model of CRS
TL;DR: Evidence is shown that the ARTEMISTM receptor disentangles efficacy from CRS and holds the potential to be a clinically safer therapy by preventing ACT-triggered CRS, and limiting IL-6 expression could improve the safety of adoptive T-cell therapies.
Journal ArticleDOI
Chimeric Immunoreceptor (T-Body) Targeting of Acute B-Cell Lymphoblastic Leukemia (B-ALL) through Lentivirus Engineering of Primary Human T Cells.
Michael C. Milone,Jonathan D. Fish,Carmine Carpenito,Mehdi Lakal,Ella Ofori,Gwenn Danet-Desnoyers,James L. Riley,Stephan A. Grupp,Carl H. June +8 more
TL;DR: It is shown that lentiviral-engineered T cells expressing anti-CD19 T bodies efficiently kill CD19 expressing cell lines and primary B-ALL cells in an antigen-specific manner and suggests that distinct combinatorial signaling domains may be required for optimal function in CD4 and CD8 engineered T cells.
Journal ArticleDOI
Pooled Analysis of Day +100 Survival for Defibrotide-Treated Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) and Ventilator or Dialysis Dependence Following Hematopoietic Stem Cell Transplantation (HSCT)
Paul G. Richardson,Angela R. Smith,Nancy A. Kernan,Joseph H. Antin,Leslie Lehmann,Robert J. Ryan,Robin Hume,William Tappe,Stephan A. Grupp +8 more
TL;DR: In this article, a pooled analysis compared overall survival among groups based on severity of VOD/SOS, including those with MOD and those who were ventilator- or dialysis-dependent.